Sarepta Gene Therapy Setbacks - Search News

Order byBest matchMost fresh

News

Sarepta, gene therapy and Europe

· 1d · on MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics suffered another major setback on Friday as Europe's drug regulator decided not to recommend the approval of Elevidys, following mounting regulatory scrutiny and two recent patient deaths linked to the company's gene therapy.

Continue reading

BioPharma Dive · 1d

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Devdiscourse14m

Health Sector Headlines: Shifts in Profits, Drug Developments, and Data-Sharing Innovations

HCA Healthcare raises 2025 profit forecast amidst insurance uncertainty while Centene anticipates a 2026 profitability boost ...

3don MSN

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

4don MSN

Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy

After the FDA request, Cambridge, Massachusetts-based Sarepta said in a statement that it will continue to ship the therapy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results